progression-free survival

You have access
Salvage-line of Capecitabine Plus Oxaliplatin Therapy (XELOX) for Patients With Inoperable/Advanced Gastric Cancer Resistant/Intolerant to Cisplatin (OGSG1403)
NAOTOSHI SUGIMOTO, JUNJI KAWADA, YOSHIO OKA, SHUGO UEDA, KOHEI MURAKAMI, KAZUHIRO NISHIKAWA, YUKINORI KUROKAWA, KAZUMASA FUJITANI, HISATO KAWAKAMI, SHUNJI ENDO, DAISUKE SAKAI, TOSHIO SHIMOKAWA and TAROH SATOH

Anticancer Research January 2025, 45 (1) 307-313; DOI: https://doi.org/10.21873/anticanres.17418
Open Access
Preoperative Tumor Growth Rate Does Not Predict Overall or Progression-free Survival in Patients With Glioblastoma
JAN LEPPERT, CLAUDIA DITZ, JAKOB MATSCHKE, MARIA.VITTORIA MATONE, PATRICK KUPPLER, CHRISTINA HILLBRICHT, HARALD KRENZLIN, NAUREEN KERIC, HANNES SCHACHT, CHRISTIAN ZIEMANN, ELISA MARIA GROH, LARYSA LIUBICH, OKSANA ZEMSKOVA, DIRK RADES and ANASTASSIA LÖSER

Anticancer Research November 2024, 44 (11) 5043-5049; DOI: https://doi.org/10.21873/anticanres.17328
You have access
Awake Surgery for Right Frontal Lobe Glioma: Preserving Emotional Recognition and Facilitating Early Return to Work
KOSEI YAMAMOTO, RYOTA TAMURA, SOTA WAKAHARA, KAZUHIRO KOJIMA, MAKIKO ANDO, MASAHIRO YO, KENZO KOSUGI, YOHEI KITAMURA, RYO UEDA, AIKO ISHIKAWA, TETSUYA TSUJI and MASAHIRO TODA

Anticancer Research October 2024, 44 (10) 4609-4615; DOI: https://doi.org/10.21873/anticanres.17291
Open Access
Genetic Alteration of p18^INK4C and its Expression in Peripheral Blood Mononuclear Cells Were Not Associated With Progression-free Survival of Multiple Myeloma Patients After Autologous Stem Cell Transplant
JUNAN LI and MING J. POI

Anticancer Research September 2024, 44 (9) 3771-3776; DOI: https://doi.org/10.21873/anticanres.17201
Open Access
The Predictive Value of Different Glasgow Prognostic Scores and the LabBM Score for Patients With Recurrent Glioblastoma
DIRK RADES, OKSANA ZEMSKOVA, JAN LEPPERT and NATHAN Y. YU

Anticancer Research September 2024, 44 (9) 3973-3981; DOI: https://doi.org/10.21873/anticanres.17226
Open Access
Prognostic Factors for Progression-free Survival and Overall Survival After Recurrence of Glioblastoma
OKSANA ZEMSKOVA, NATHAN Y. YU, JAN LEPPERT and DIRK RADES

Anticancer Research July 2024, 44 (7) 3059-3066; DOI: https://doi.org/10.21873/anticanres.17119
You have access
Real Clinical Practice of Combined Atezolizumab Plus Chemotherapy in Patients With Small Cell Lung Cancer
SATOSHI ANO, NORIHIRO KIKUCHI, SHINICHIRO OKAUCHI, TAKESHI NUMATA, RYOTA NAKAMURA, TOSHIHIRO SHIOZAWA, HIROKO WATANABE, TOMOHIRO TAMURA, KUNIHIKO MIYAZAKI, SHIGEN HAYASHI, TAKAAKI YAMASHITA, KOICHI KURISHIMA, MASAHARU INAGAKI, TAKAYUKI KABURAGI, TAKEO ENDO, HIROAKI SATOH and NOBUYUKI HIZAWA

Anticancer Research June 2024, 44 (6) 2725-2730; DOI: https://doi.org/10.21873/anticanres.17080
You have access
Results of Definitive (Chemo)radiotherapy Using Computed Tomography-based Brachytherapy for Cervical Cancer
TOMOMI AOSHIKA, SHIN-EI NODA, TAKANORI ABE, YU KUMAZAKI, RYUTA HIRAI, MITSUNOBU IGARI, SATOSHI SAITO, YASUHIRO RYUNO, MISAKI IINO, YUGA TAKEDA, TOMOHIRO OHTA, JUN WATANABE, KEITA TSUKAHARA and SHINGO KATO

Anticancer Research April 2024, 44 (4) 1583-1589; DOI: https://doi.org/10.21873/anticanres.16956
You have access
Relationship Between Adverse Events and Progression-free Survival in Patients Receiving Cabozantinib for Previously Treated Metastatic Renal Cell Carcinoma
RYO SATO, YUTO MATSUSHITA, AYANA TAKEMURA, MOMOKO SUGIYAMA, KYOHEI WATANABE, HIROMITSU WATANABE, KEITA TAMURA, DAISUKE MOTOYAMA, MASAO NAGATA, ATSUSHI OTSUKA, HIROSHI FURUSE and HIDEAKI MIYAKE

Anticancer Research February 2024, 44 (2) 781-786; DOI: https://doi.org/10.21873/anticanres.16869
You have access
Atezolizumab for EGFR-mutated Non-small Cell Lung Cancer Patients: An Observation Study in Ibaraki Group (ATTENTION-IBARAKI)
TOMOHIRO TAMURA, TAKESHI NUMATA, HIDETOSHI YANAI, RYOTA NAKAMURA, TOSHIHIRO SHIOZAWA, HIROKO WATANABE, SHINICHIRO OKAUCHI, NORIHIRO KIKUCHI, KUNIHIKO MIYAZAKI, SHIGEN HAYASHI, TAKAAKI YAMASHITA, KOICHI KURISHIMA, MASAHARU INAGAKI, HIROAKI SATOH, HIROICHI ISHIKAWA, TAKAYUKI KABURAGI, TAKEO ENDO, TORU SAKAMOTO and NOBUYUKI HIZAWA

Anticancer Research October 2023, 43 (10) 4583-4591; DOI: https://doi.org/10.21873/anticanres.16652

Main menu

User menu

Search

progression-free survival

Pages